Diagnosis and management of Pompe disease
- PMID: 25118547
- DOI: 10.7196/samj.7386
Diagnosis and management of Pompe disease
Abstract
Pompe disease (PD) is an autosomal-recessively inherited neuromuscular disease that, if not diagnosed and treated early, can be fatal. It can present from early infancy into adulthood. Due to the lack of acid alpha-glucosidase, there is progressive intracellular accumulation of glycogen. The severity of the disease is determined by age of onset, organ involvement including the degree of severity of muscle involvement, as well as rate of progression. PD is classified into two groups: infantile and late-onset, each having two subgroups. The need for two tests performed by separate methods (screening and confirmatory) is outlined. It is imperative to try to reduce the time to diagnosis and to recognise the possibilities of false-positive results. A multidisciplinary team approach to treatment of affected patients is optimum with, as team leader, a physician who has experience in managing this rare disorder. In this article, we present a brief overview of the disease and provide guidelines for diagnosis and management of this condition in South Africa.
Similar articles
-
The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):1-7. doi: 10.1002/ajmg.c.31324. Epub 2012 Jan 17. Am J Med Genet C Semin Med Genet. 2012. PMID: 22253049
-
Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.J Clin Neuromuscul Dis. 2008 Jun;9(4):421-31. doi: 10.1097/CND.0b013e318176dbe4. J Clin Neuromuscul Dis. 2008. PMID: 18525427 Review.
-
Pompe disease: pathogenesis, molecular genetics and diagnosis.Aging (Albany NY). 2020 Aug 3;12(15):15856-15874. doi: 10.18632/aging.103794. Epub 2020 Aug 3. Aging (Albany NY). 2020. PMID: 32745073 Free PMC article. Review.
-
The generation of induced pluripotent stem cells (iPSCs) from patients with infantile and late-onset types of Pompe disease and the effects of treatment with acid-α-glucosidase in Pompe's iPSCs.Mol Genet Metab. 2014 May;112(1):44-8. doi: 10.1016/j.ymgme.2014.02.012. Epub 2014 Mar 4. Mol Genet Metab. 2014. PMID: 24642446
-
Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.Am J Med Genet C Semin Med Genet. 2012 Feb 15;160C(1):50-8. doi: 10.1002/ajmg.c.31320. Epub 2012 Jan 17. Am J Med Genet C Semin Med Genet. 2012. PMID: 22252961
Cited by
-
The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.BMC Neurol. 2017 Nov 22;17(1):202. doi: 10.1186/s12883-017-0983-2. BMC Neurol. 2017. PMID: 29166883 Free PMC article.
-
Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.J Neurol. 2019 Aug;266(8):2010-2017. doi: 10.1007/s00415-019-09373-2. Epub 2019 May 18. J Neurol. 2019. PMID: 31104135 Review.
-
Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy.Chin Med J (Engl). 2017 Oct 5;130(19):2393-2394. doi: 10.4103/0366-6999.215340. Chin Med J (Engl). 2017. PMID: 28937052 Free PMC article. No abstract available.
-
Case report: Chronic pain in a pediatric patient with late-onset pompe disease.Front Pain Res (Lausanne). 2023 Oct 6;4:1244609. doi: 10.3389/fpain.2023.1244609. eCollection 2023. Front Pain Res (Lausanne). 2023. PMID: 37841659 Free PMC article.
-
Rodent models for resolving extremes of exercise and health.Physiol Genomics. 2016 Feb;48(2):82-92. doi: 10.1152/physiolgenomics.00077.2015. Epub 2015 Sep 22. Physiol Genomics. 2016. PMID: 26395598 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous